TVT 2016 is a three-day course featuring the latest research and state-of-the-art techniques for transcatheter aortic and mitral valve therapies. This year's conference will emphasize advanced imaging, bioskill demonstrations, and live case transmissions featuring the world's leading experts. The agenda is now available online at: http://www.
Sessions showcasing the latest research will focus on updates and new insights from transcatheter valve trials and registries in lower surgical risk patients. Among the trials that will be discussed are:
- Highlights From PARTNER 2A in Intermediate-Risk Patients
Michael J. Mack
- Updates From NOTION: The First All-Comer TAVR Trial
- Highlights From the SAPIEN 3 Experience in Intermediate-Risk Patients
Vinod H. Thourani
- Updates From SURTAVI in Intermediate-Risk Patients
Jeffrey J. Popma
- Updates From the UK All-Comer TAVR Study
Neil E. Moat
- Study Design for the EVOLUT R Low-Risk Trial
Jeffrey J. Popma
- Study Design for the PARTNER 3 Low-Risk Trial
Martin B. Leon
The meeting will also examine:
- Direct and indirect annuloplasty devices
- New access site management systems (transfemoral and transapical)
- New TAVR accessories including balloon valvuloplasty devices, access site closure technologies, guidewires and sheath technologies, cerebral embolic protection technologies, and imaging systems
Valvular heart disease affects a large number of people who require diagnostic procedures and long-term management. Many patients have no symptoms, but for others, if not treated, advanced heart valve disease can lead to heart failure, stroke, blood clots, or death due to sudden cardiac arrest. Traditionally, valvular heart disease has been treated with surgical repair or replacement. Over the last several years, there have been important advances in concepts, tools, techniques, and patient selection using nonsurgical procedures. Transcatheter valve intervention offers the potential to reduce the procedural morbidity, mortality, and costs of surgical valve replacement or repair while accelerating patient recovery.
June 16-18, 2016
Sheraton Grand Chicago
301 East North Water Street
The course directors for TVT 2016 are:
Martin B. Leon, MD
NewYork-Presbyterian Hospital/Columbia University Medical Center
Francesco Maisano, MD
Nicolo Piazza, MD, PhD
McGill University Health Center
Mark Reisman, MD
University of Washington Medical Center/Regional Heart Center
Gregg W. Stone, MD
New York-Presbyterian Hospital/Columbia University Medical Center
John G. Webb, MD
St. Paul's Hospital
HOW TO REGISTER:
Media may apply for registration by emailing email@example.com.
Can't attend in person? Reporters are eligible for access to Virtual TVT which provides live and on-demand viewing of the meeting sessions.
The Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and has educated doctors on the latest treatments for heart disease. For more information, visit http://www.